Physician’s Briefing Weekly Coronavirus Roundup
FDA Moves to Resume Use of J&J COVID Vaccine
Johnson & Johnson has agreed with the U.S. Food and Drug Administration to add a warning label to the vaccine
Pfizer and Moderna Vaccines Effective Against New NYC Variant
Studies add to growing evidence that the two vaccines protect against all coronavirus variants identified so far
FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum-containing chemotherapy treatment
Survivors of Adolescent, Young Adult Cancer Face Financial Hardships
Hardships include forgoing care and medication nonadherence due to cost
No Obvious Safety Signals ID’d for mRNA COVID-19 Vaccine in Pregnancy
Adverse neonatal outcomes included preterm birth and small for gestational age; no neonatal deaths reported
Dietary Patterns ID’d That Raise CVD, Mortality Risk
Linear association with total CVD, all-cause mortality seen for pattern including high intakes of chocolate, confectionary, butter, low-fiber bread
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes
Icodec results in greater increase in time-in-range versus once-daily insulin glargine U100 in two phase 2 randomized, open-label trials
Guidance Updated for Assessing Allergy Risk of COVID-19 Vaccines
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
Sacituzumab Govitecan Treats Metastatic Triple-Negative Breast Cancer
Progression-free, overall survival prolonged with sacitizumab govitecan versus single-agent chemotherapy
